Compare · OMIC vs WAT
OMIC vs WAT
Side-by-side comparison of Singular Genomics Systems Inc. (OMIC) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMIC and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $36.09B, about 74.0x OMIC ($487.8M).
- WAT has hit the wire 4 times in the past 4 weeks while OMIC has been quiet.
- WAT has more recent analyst coverage (25 ratings vs 5 for OMIC).
- Company
- Singular Genomics Systems Inc.
- Waters Corporation
- Price
- $19.98+0.35%
- $371.08+0.95%
- Market cap
- $487.8M
- $36.09B
- 1M return
- -
- +3.71%
- 1Y return
- -
- +29.35%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1995
- News (4w)
- 0
- 4
- Recent ratings
- 5
- 25
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R
Latest WAT
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)
- Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
- Bernstein resumed coverage on Waters with a new price target
- SVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Waters Corporation
- IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
- Piper Sandler initiated coverage on Waters with a new price target
- Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis